Relationship between membrane fatty acids and cognitive symptoms and information processing in individuals at ultra-high risk for psychosis

Schizophrenia Research

Volumn 158, Issue 1-3, 2014, Pages 39-44

  Kim, Sung Wan ^a   Schäfer, Miriam R ^b,c   Klier, Claudia M ^d   Berk, Michael ^b,e   Rice, Simon ^b   Allott, Kelly ^b   Bartholomeusz, Cali F ^f   Whittle, Sarah L ^f   Pilioussis, Eleanor ^f   Pantelis, Christos ^f   McGorry, Patrick D ^b   Amminger, G Paul ^b,c  

^a Chonnam National University Medical School   (South Korea)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d UNIV KLIN KINDER JUGENDHEILKUNDE   (Austria)

^e DEAKIN UNIVERSITY   (Australia)

^f UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Cognitive symptom; Eicosenoic acid; Intracranial area; Membrane fatty acid; Schizophrenia; Ultra high risk

Indexed keywords

15 TETRACOSENOIC ACID; 5,8,11 ICOSATRIENOIC ACID; ADRENIC ACID; ALPHA INOLENIC ACID; ARACHIDONIC ACID; CERVONIC ACID; DOCOSADIENOIC ACID; DOCOSAHEXAENOIC ACID; DOCOSAPENTAENOIC ACID; ELAIDIC ACID; ERUCIC ACID; FATTY ACID; GAMMA LINOLENIC ACID; HEPTADECANOIC ACID; HOMOGAMMA LINOLEIC ACID; ICOSAPENTAENOIC ACID; LINOLEIC ACID; MYRISTIC ACID; OLEIC ACID; OMEGA 9 EICOSENOIC ACID; PALMITIC ACID; SEDATIVE AGENT; STEARIC ACID; UNCLASSIFIED DRUG; VACCENIC ACID;

ADOLESCENT; ADULT; ARTICLE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE ASSOCIATION; ERYTHROCYTE MEMBRANE; FATTY ACID METABOLISM; FEMALE; FUNCTION TEST; GAS CHROMATOGRAPHY; HIGH RISK POPULATION; HUMAN; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MALE; NERVE CELL DIFFERENTIATION; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA; SEX DIFFERENCE; ULTRA HIGH RISK POPULATION; ZAHLEN VERBINDUNGS TEST; BRAIN; CELL MEMBRANE; ERYTHROCYTE; METABOLISM; ORGAN SIZE; PATHOLOGY; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; REGRESSION ANALYSIS; RISK; YOUNG ADULT;

ADOLESCENT; ADULT; BRAIN; CELL MEMBRANE; CHROMATOGRAPHY, GAS; COGNITION DISORDERS; ERYTHROCYTES; FATTY ACIDS; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; ORGAN SIZE; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; REGRESSION ANALYSIS; RISK; YOUNG ADULT;

EID: 84906936588     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2014.06.032     Document Type: Article

References (34)

1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 1994, American Psychiatric Press Inc., Washington DC. 4th ed.
2. Amminger G.P., Schäfer M.R., Papageorgiou K., Klier C.M., Cotton S.M., Harrigan S.M., Mackinnon A., McGorry P.D., Berger G.E. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch. Gen. Psychiatry 2010, 67:146-154.
3. Amminger G.P., Schäfer M.R., Klier C.M., Slavik J.M., Holzer I., Holub M., Goldstone S., Whitford T.J., McGorry P.D., Berk M. Decreased nervonic acid levels in erythrocyte membranes predict psychosis in help-seeking ultra-high-risk individuals. Mol. Psychiatry 2012, 17:1150-1152.
4. Andreasen N.C., Endicott J., Spitzer R.L., Winokur G. The family history method using diagnostic criteria. Reliability and validity. Arch. Gen. Psychiatry 1977, 34:1229-1235.
5. Barch D.M., Bustillo J., Gaebel W., Gur R., Heckers S., Malaspina D., Owen M.J., Schultz S., Tandon R., Tsuang M., Van Os J., Carpenter W. Logic and justification for dimensional assessment of symptoms and related clinical phenomena in psychosis: relevance to DSM-5. Schizophr. Res. 2013, 150:15-20.
6. Bondi C.O., Taha A.Y., Tock J.L., Totah N.K., Cheon Y., Torres G.E., Rapoport S.I., Moghaddam B. Adolescent behavior and dopamine availability are uniquely sensitive to dietary omega-3 fatty acid deficiency. Biol. Psychiatry 2014, 75:38-46.
7. Bora E., Murray R.M. Meta-analysis of cognitive deficits in ultra-high risk to psychosis and first-episode psychosis: do the cognitive deficits progress over, or after, the onset of psychosis?. Schizophr. Bull. 2014, 40:744-755.
8. Bu B., Ashwood P., Harvey D., King I.B., Water J.V., Jin L.W. Fatty acid compositions of red blood cell phospholipids in children with autism. Prostaglandins Leukot. Essent. Fat. Acids 2006, 74:215-221.
9. De Herdt A.1., Wampers M., Vancampfort D., De Hert M., Vanhees L., Demunter H., Van Bouwel L., Brunner E., Probst M. Neurocognition in clinical high risk young adults who did or did not convert to a first schizophrenic psychosis: a meta-analysis. Schizophr. Res. 2013, 149:48-55.
10. Emsley R., Rabinowitz J., Torreman M., RIS-INT-35 Early psychosis global working group. The factor structure for the Positive and Negative Syndrome Scale (PANSS) in recent-onset psychosis. Schizophr. Res. 2003, 61:47-57.
11. Eritaia J., Wood S.J., Stuart G.W. An optimized method for estimating intracranial volume from magnetic resonance images. Magn. Reson. Med. 2000, 44:973-977.
12. Ferguson K.J., Wardlaw J.M., Edmond C.L., Deary I.J., Maclullich A.M. Intracranial area: a validated method for estimating intracranial volume. J. Neuroimaging 2005, 15:76-78.
13. Fusar-Poli P., Byrne M., Valmaggia L., Day F., Tabraham P., Johns L., McGuire P., OASIS Team Social dysfunction predicts two years clinical outcome in people at ultra high risk for psychosis. J. Psychiatr. Res. 2010, 44:294-301.
14. Gama C.S., Canever L., Panizzutti B., Gubert C., Stertz L., Massuda R., Pedrini M., de Lucena D.F., Luca R.D., Fraga D.B., Heylmann A.S., Deroza P.F., Zugno A.I. Effects of omega-3 dietary supplement in prevention of positive, negative and cognitive symptoms: a study in adolescent rats with ketamine-induced model of schizophrenia. Schizophr. Res. 2012, 141:162-167.
15. Haijma S.V., Van Haren N., Cahn W., Koolschijn P.C., Hulshoff Pol H.E., Kahn R.S. Brain volumes in schizophrenia: a meta-analysis in over 18,000 subjects. Schizophr. Bull. 2013, 39:1129-1138.
16. Hoen W.P., Lijmer J.G., Duran M., Wanders R.J., van Beveren N.J., de Haan L. Red blood cell polyunsaturated fatty acids measured in red blood cells and schizophrenia: a meta-analysis. Psychiatry Res. 2013, 207:1-12.
17. Iuliano L., Pacelli A., Ciacciarelli M., Zerbinati C., Fagioli S., Piras F., Orfei M.D., Bossù P., Pazzelli F., Serviddio G., Caltagirone C., Spalletta G. Plasma fatty acid lipidomics in amnestic mild cognitive impairment and Alzheimer's disease. J. Alzheimers Dis. 2013, 36:545-553.
18. Jenkinson M., Smith S. Optimization in Robust Linear Registration of Brain Images (No. TR00MJ2) 2000, University of Oxford, Oxford.
19. Kahn R.S., Keefe R.S. Schizophrenia is a cognitive illness: time for a change in focus. J.A.M.A. Psychiatry 2013, 70:1107-1112.
20. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13:261-276.
21. McGorry P.D., Yung A.R., Phillips L.J., Yuen H.P., Francey S., Cosgrave E.M., Germano D., Bravin J., McDonald T., Blair A., Adlard S., Jackson H. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch. Gen. Psychiatry 2002, 59:921-928.
22. Mohamed S., Paulsen J.S., O'Leary D., Arndt S., Andreasen N. Generalized cognitive deficits in schizophrenia: a study of first-episode patients. Arch. Gen. Psychiatry 1999, 56:749-754.
23. Morrison A.P., French P., Walford L., Lewis S.W., Kilcommons A., Green J., Parker S., Bentall R.P. Cognitive therapy for the prevention of psychosis in people at ultra-high risk: randomised controlled trial. Br. J. Psychiatry 2004, 185:291-297.
24. Nuss P., Tessier C., Ferreri F., De Hert M., Peuskens J., Trugnan G., Masliah J., Wolf C. Abnormal transbilayer distribution of phospholipids in red blood cell membranes in schizophrenia. Psychiatry Res. 2009, 169:91-96.
25. Nuss P., Bergaoui H., Tessier C., Fragerman A., Lamaziere A., Sweers K., De Hert M. The increased number of phospholipid abnormalities observed in the erythrocyte membrane of schizophrenia patients is associated with increased psychopathology. Schizophr. Res. 2014, 153(Suppl.):360.
26. Ohara K. The n-3 polyunsaturated fatty acid/dopamine hypothesis of schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007, 31. (469-467).
27. Oswald W.D., Roth E. Der Zahlen-Verbindungs-Test (ZVT) Göttingen: Hogrefe 1987.
28. Paik M.J., Li W.Y., Ahn Y.H., Lee P.H., Choi S., Kim K.R., Kim Y.M., Bang O.Y., Lee G. The free fatty acid metabolome in cerebral ischemia following human mesenchymal stem cell transplantation in rats. Clin. Chim. Acta 2009, 402:25-30.
29. Rammsayer T.H., Stahl J. Identification of sensorimotor components accounting for individual variability in Zahlen-Verbindungs-Test (ZVT) performance. Intelligence 2007, 35:623-630.
30. Sgouros S., Goldin J.H., Hockley A.D., Wake M.J., Natarajan K. Intracranial volume change in childhood. J. Neurosurg. 1999, 91:610-616.
31. Smith S.M. Fast robust automated brain extraction. Hum. Brain Mapp. 2002, 17:143-155.
32. Sumiyoshi T., Matsui M., Itoh H., Higuchi Y., Arai H., Takamiya C., Kurachi M. Essential polyunsaturated fatty acids and social cognition in schizophrenia. Psychiatry Res. 2008, 157:87-93.
33. Yang J., Chen T., Sun L., Zhao Z., Qi X., Zhou K., Cao Y., Wang X., Qiu Y., Su M., Zhao A., Wang P., Yang P., Wu J., Feng G., He L., Jia W., Wan C. Potential metabolite markers of schizophrenia. Mol. Psychiatry 2013, 18:67-78.
34. Yung A.R., Phillips L.J., McGorry P.D., McFarlane C.A., Francey S., Harrigan S., Patton G.C., Jackson H.J. Prediction of psychosis. A step towards indicated prevention of schizophrenia. Br. J. Psychiatry Suppl. 1998, 172:14-20.